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Abstract Cell systems derived from knockout mice for the
insulin receptor (IR) or the IGF-1 receptor (IGF-1R) represent
unique tools for dissecting complex interplay in the actions of
insulin and insulin-like growth factors through their cognate
versus non-cognate receptor. In this study, we used a fibroblast
cell line derived from IR-deficient mice to investigate metabolic
and mitogenic effects of IGF-1 and insulin. IGF-1 was able to
stimulate glucose uptake, glucose incorporation into glycogen
and thymidine incorporation in such cells. Phosphatidylinositol 3-
kinase and mitogen-activated protein kinase, two enzymes of
major metabolic-mitogenic signaling pathways, were activated
upon stimulating these cells with IGF-1. All these effects were
also achieved when IR-deficient cells were stimulated with
insulin. Thus, IGF-1R can represent an alternative receptor
through which insulin might exert some of its effects.
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1. Introduction
Insulin and insulin-like growth factors (IGF-1 and IGF-2)
lead to a variety of biological e¡ects mediated by the insulin
receptor (IR) and the type 1 receptor for IGFs (IGF-1R),
respectively, which have very similar heterodimeric K2L2
structure and belong to the family of receptor tyrosine kinases
[1]. The analysis of the metabolic and mitogenic e¡ects medi-
ated by IR and IGF-1R in vivo is complicated for a number
of reasons. The two receptors are present on the surface of
most of the cells in the body although their relative propor-
tions vary in di¡erent tissues. The two receptors activate com-
mon intracellular signaling pathways, i.e. the phosphatidyl-
inositol 3-kinase (PI 3-kinase) and the mitogen-activated
protein kinase (MAP kinase) pathways, by the same mecha-
nisms [2,3]. These receptors can bind the heterologous ligands,
albeit with lower a⁄nities [4]. Finally, some biological e¡ects
might be achieved through IR/IGF-1R hybrid receptors [5].
The analysis of various knockout mice carrying null muta-
tions in genes encoding these ligands or their receptors [6^11]
has shed some light on the issues of speci¢city and redun-
dancy in the insulin and IGF system in vivo. It is interesting
to brie£y present certain striking features of the phenotype of
some of these mutants in which homologous ligand/receptor
interactions were abolished and heterologous interactions
could be forced to take place.
IGF-1R de¢ciency resulted in marked intrauterine growth
retardation and several abnormalities of di¡erentiation in var-
ious tissues leading to immediate lethality at birth [8]. Inter-
estingly, mutant mice lacking both IGF-1R and the IGF-2/
mannose-6-phosphate receptor (IGF-2R) which functions in
clearing IGF-2 from the circulation were viable [12]. In this
situation, e⁄cient interaction of IGF-2 with IR could take
place due to elevated IGF-2 levels. Therefore, IGF-2 action
through IR could completely compensate for IGF-1R de¢-
ciency. The ability of IGF-2 to lead to biological e¡ects via
IR was further demonstrated using IGF-1R-de¢cient ¢bro-
blasts [13].
On the other hand, IR-de¢cient pups were nearly normal at
birth but developed severe diabetes mellitus with ketoacidosis
leading to death within 1 week [11]. Interestingly, insulin-de-
¢cient pups developed the same metabolic disorders but more
rapidly and died sooner [9]. Since IR-de¢cient mice became
hyperinsulinemic, one could wonder whether insulin, at high
concentrations, might exert some of its e¡ects through IGF-
1R. This issue was further addressed here by examining the
ability of IGF-1 and insulin to lead to metabolic and mito-
genic e¡ects and to activate PI 3-kinase and MAP kinase
through IGF-1R using a ¢broblast cell line derived from
IR-de¢cient mice.
2. Materials and methods
2.1. Cell cultures
Primary cultures of ¢broblasts from IR-de¢cient newborn pups
were obtained as described [14]. Brie£y, heart and kidneys were
minced and incubated with trypsin for 30 min at 37‡C. After centrif-
ugation, the cells were plated into culture dishes in Dulbecco’s modi-
¢ed Eagle’s medium (DMEM; Gibco-BRL)/10% fetal bovine serum.
After a few passages of cells maintained at subcon£uent levels, pri-
mary cultures underwent crisis and a cell line was recovered. It was
veri¢ed that these cells carried a homozygous null mutation for IR by
genotype analysis of cellular DNA [11]. Cells were grown to con£u-
ence in 24-well plates for metabolic and mitogenic assays and in 6-well
plates for the PI 3-kinase and MAP kinase assays.
2.2. 2-Deoxyglucose uptake
The uptake of 2-deoxyglucose was measured essentially as follows.
Brie£y, cells were serum-starved for 18 h in DMEM with low glucose/
0.1% bovine serum albumin (BSA) and then incubated for 2 h at 37‡C
in DMEM without glucose. The cells were washed with phosphate-
bu¡ered saline (PBS), preincubated for 40 min in 1 ml of HEPES
bu¡er (50 mM HEPES pH 7.4, 140 mM NaCl, 1.85 mM CaCl2, 1.3
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mM MgSO4, 4.8 mM KCl)/0.1% BSA and stimulated with human
recombinant IGF-1 (Gro Pep) or insulin (Sigma) for 10 min at
37‡C prior to incubation with 0.1 mM 2-deoxyglucose (Sigma) and
1 WCi 2-deoxy-D-[2,6-3H]glucose (25^55 Ci/mmol; Amersham) for 10
min at 37‡C. Cells were washed with cold PBS, solubilized in 250 Wl
1 N NaOH and the solution was neutralized with 250 Wl 1 N HCl
before counting the radioactivity.
2.3. Glucose incorporation into glycogen
Glucose incorporation into glycogen was performed as described
[15]. Cells were serum-starved as for the 2-deoxyglucose uptake assay
and then incubated in DMEM containing 2.5 mM glucose, 0.1% BSA
and 25 mM HEPES pH 7.4 for 3 h at 37‡C. The cells were washed
with PBS, stimulated with IGF-1 or insulin for 30 min at 37‡C and
incubated in the presence of 1 WCi D-[U-14C]glucose (250 mCi/mmol;
Amersham) for 90 min. Cells were then rinsed with PBS, solubilized
with 250 Wl 30% KOH for 30 min at 37‡C and samples were boiled for
30 min with carrier glycogen at 1 mg/ml. Glycogen was precipitated
with 95% ethanol at 4‡C during 1 h, recovered on Whatman glass
¢lters that were washed with ice-cold 70% ethanol and their radio-
activity was counted.
2.4. Thymidine incorporation into DNA
Con£uent cells were grown to quiescence in DMEM/0.5% BSA for
72 h. The ligands (IGF-1 or insulin) were then added to the wells for
16 h prior to a 2-h pulse with 1 WCi or [methyl-3H]thymidine (25 Ci/
mmol; Amersham). The cells were washed twice respectively in cold
PBS, 5% trichloroacetic acid (TCA) and 95% ethanol and then dis-
solved in 250 Wl 1 N NaOH. The solution was neutralized with 250 Wl
1 N HCl and the radioactivity was counted.
2.5. Assay of PI 3-kinase activity
PI 3-kinase activity was measured essentially as described [16].
Brie£y, cells were serum-starved for 18 h in DMEM/0.2% BSA, stimu-
lated with IGF-1 or insulin for 10 min at 37‡C, washed with PBS and
solubilized in lysis bu¡er (50 mM HEPES pH 7.5, 150 mM NaCl,
1 mM EDTA pH 8, 10% glycerol, 1% Triton X-100, 20 mM sodium
pyrophosphate, 2 mM orthovanadate pH 10, 100 mM NaF, 2 mM
phenylmethylsulfonyl, 20 Wg/ml aprotinin, 20 Wg/ml leupeptin and 0.7
Wg/ml pepstatin). The lysates were immunoprecipitated using 5 Wg
anti-phosphotyrosine antibodies (PY20; Transduction Laboratories)
and protein A-Sepharose (Pharmacia) for 3 h at 4‡C. The immuno-
precipitates were washed three times with lysis bu¡er, three times with
the reaction bu¡er (20 mM HEPES pH 7.5, 0.4 mM EDTA and 0.4
mM sodium pyrophosphate) and pellets were resuspended in 30 Wl of
the reaction bu¡er. L-K-Phosphatidylinositol (Sigma) was added (10 Wl
of a sonicated solution at 10 mg/ml in 5 mM HEPES pH 7.5) and the
reaction was initiated by addition of 10 Wl of a mixture containing
1 WCi [Q-32P]ATP (4500 Ci/mmol; ICN), 50 mM MgCl2, 0.25 mM
HEPES pH 7.5, 0.24 mM EDTA and 0.24 mM sodium pyrophos-
phate. After 15 min incubation at room temperature with shaking, the
reaction was stopped by adding 15 Wl 4 M HCl and 130 Wl CHCl3/
methanol (1:1). The samples were centrifuged and the lower organic
phases containing phospholipids were subjected to thin layer chroma-
tography (TLC; Merck) performed in CHCl3/CH3OH/NH4OH/H2O
(45:35:7:3) and the TLC plates were exposed to X-ray ¢lms for 24 h.
2.6. MAP kinase assay
Cells were serum-staved, stimulated with IGF-1 or insulin for var-
ious times and solubilized as for the PI 3-kinase assays. The lysates
were immunoprecipitated using antibodies against extracellular regu-
lated kinase (ERK)-1 and ERK-2 (1 Wg each; Santa Cruz) and protein
A-Sepharose for 3 h at 4‡C. The immunoprecipitates were washed
three times with lysis bu¡er, three times with the reaction bu¡er (20
mM HEPES, 150 mM NaCl, 0.1% Triton X-100, 10% glycerol) and
pellets were resuspended in 40 Wl of the reaction bu¡er. 10 Wl of the
reaction mixture containing 50 mM MgCl2, 1 mg/ml myelin basic
protein (MBP; Sigma), 0.25 mM ATP and 25 mM dithiothreitol
was added and the reaction was initiated by addition of 0.5 Wl [Q-
32P]ATP (4500 Ci/mmol; ICN). After 30 min incubation at room
temperature with shaking, the reaction was stopped by spotting the
whole samples on Whatman P81 ¢lters that were washed once in 10%
TCA, three times in 5% TCA, three times in 1% TCA containing 240
mM sodium pyrophosphate and rinsed with ethanol. The ¢lters were
dried and the radioactivity was counted.
3. Results and discussion
The role that IGFs play in cellular growth and di¡erentia-
tion is very well documented. Although there are a number of
reports indicating that IGF-1 can lead to metabolic e¡ects and
that IGF-1R possesses certain metabolic potential [17^23], the
lethal phenotype of IR-de¢cient mice indicates that IGF-1R
cannot entirely substitute for the absence of IR [10,11]. Mu-
tant mice lacking IR or IR-de¢cient cellular systems that can
be derived from these mutants represent unique tools to re-
investigate the metabolic potential of IGF-1R in the absence
of IR. In the present study, some metabolic and mitogenic
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Fig. 1. Stimulation of glucose transport in IR-de¢cient ¢broblasts
by IGF-I or insulin. Serum-starved cells were incubated in DMEM
without glucose, stimulated in HEPES bu¡er by increasing concen-
trations of IGF-I or insulin, followed by incubation with [3H]-2-de-
oxyglucose. The cells were then washed, solubilized and the radioac-
tivity was counted. A blank value obtained with unstimulated cells
was subtracted. Results are presented as the means þ S.E.M. of 10
separate experiments.
Fig. 2. Glucose incorporation into glycogen in IR-de¢cient ¢bro-
blasts stimulated by IGF-I or insulin. Serum-starved cells were
stimulated by increasing concentrations of IGF-I or insulin and
then incubated with [14C]glucose. The cells were washed, solubilized
and boiled. Glycogen was precipitated, recovered by ¢ltration on
Whatman GFB ¢lters and the radioactivity was counted. A blank
value obtained with unstimulated cells was subtracted. The data are
the means þ S.E.M. of 10 separate experiments.
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actions of IGF-1 as well as activation of PI 3-kinase and
MAP kinase were examined using an IR-de¢cient ¢broblast
cell line. In parallel, the ability of insulin to lead to these
e¡ects mediated by IGF-1R was investigated in such cells.
3.1. Metabolic e¡ects
Firstly, glucose uptake was measured using [3H]-2-deoxy-
glucose upon stimulation of IR-de¢cient cells with IGF-1 or
insulin. As shown in Fig. 1, IGF-1 was able to stimulate
glucose uptake in these cells. The dose-response curve for
this metabolic action of IGF-1 was a sigmoid. Stimulation
of glucose uptake was also obtained when these cells were
stimulated with insulin (Fig. 1). As for IGF-1, the dose-re-
sponse curve with insulin was also a sigmoid that was how-
ever shifted to the right, re£ecting the lower a⁄nity of insulin
for the heterologous receptor. Ten-fold higher concentrations
of insulin were required to reach e¡ects comparable to those
obtained with IGF-1. The plateau values were obtained for
IGF-1 at V1038 and for insulin at V1037 M.
Secondly, glucose incorporation into glycogen was meas-
ured using [14C]glucose upon stimulation of IR-de¢cient cells
with IGF-1 or insulin. As shown in Fig. 2, IGF-1 was able to
stimulate glucose incorporation into glycogen in these cells
and again the dose-response curve for this metabolic action
of IGF-1 was a sigmoid. The data presented in Fig. 2 also
show the ability of insulin to stimulate glucose incorporation
into glycogen in these cells. Again, the dose-response curve
with insulin was shifted rightward.
3.2. Mitogenic e¡ects
The mitogenic e¡ect is classically examined by measuring
[3H]thymidine incorporation into cellular DNA upon stimu-
lating the cells with growth factors. As expected, IGF-1 was
able to stimulate [3H]thymidine incorporation in IR-de¢cient
cells (Fig. 3). Interestingly, a bell-shaped dose-response curve
was obtained for this mitogenic action of IGF-1. The data
presented in Fig. 3 show that insulin can stimulate
[3H]thymidine incorporation in these cells as well. As for the
metabolic e¡ects, higher insulin concentrations are required to
reach e¡ects comparable to those obtained with IGF-1. In
contrast with IGF-1, the dose-response curve for the mitogen-
ic action of insulin in this system appeared to be a sigmoid in
the range of concentrations tested.
3.3. Signaling pathways activated
The activation of PI 3-kinase and MAP kinase, involved in
major metabolic and mitogenic signaling pathways activated
by IGF-1R, was examined upon stimulation of IR-de¢cient
cells with IGF-1 or insulin.
The PI 3-kinase activity was determined by analyzing phos-
phorylation of phosphatidylinositols in the presence of [Q-
32P]ATP. As shown in Fig. 4, PI 3-kinase activity was in-
creased in cells stimulated with IGF-1 as compared with the
basal activity in unstimulated cells. Insulin was also able to
stimulate PI 3-kinase activity in these cells. Comparable acti-
vation of PI 3-kinase was obtained with 10 nM IGF-1 and
100 nM insulin. Activation of PI 3-kinase was also observed
when cells were stimulated with high concentrations of IGF-1
(1 WM) or insulin (50 WM).
The MAP kinase activity was analyzed by measuring phos-
phorylation of MBP in the presence of [Q-32P]ATP. The results
of the kinetics of MAP kinase activation upon stimulation of
cells with IGF-1 at 10 nM and insulin at 100 nM are pre-
sented in Fig. 5. Clearly, both ligands were able to stimulate
MAP kinase although this activation appeared to be more
sustained with IGF-1 as compared with insulin. Similar results
were obtained in two other experiments. Activation of MAP
kinase was also observed when cells were stimulated with high
concentrations of IGF-1 or insulin (not shown).
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Fig. 4. PI 3-kinase activation by IGF-I or insulin in IR-de¢cient ¢-
broblasts. Cells were serum-starved prior to incubation with IGF-I
or insulin at the indicated concentrations. The cells were solubilized
and the lysates were immunoprecipitated with anti-phosphotyrosine
antibodies. The PI 3-kinase activity in the immunoprecipitates was
determined by phosphorylation of phosphatidylinositols in the pres-
ence of [Q-32P]ATP. Labeled phospholipids were separated by chro-
matography on TLC plates that were exposed to ¢lm and the auto-
radiogram is presented. PIP: phosphatidylinositol phosphate. ns:
unstimulated control.
Fig. 3. Incorporation of [3H]thymidine in IR-de¢cient ¢broblasts
stimulated by IGF-I or insulin. Cells maintained in serum-free me-
dium were stimulated by increasing concentrations of IGF-I or insu-
lin prior to incubation with [3H]thymidine. The cells were washed,
¢xed with TCA, dissolved and the radioactivity was counted. A
blank value obtained with unstimulated cells was subtracted. Each
value is the mean þ S.E.M. of 10 experiments.
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3.4. Limited metabolic potential of IGF-1R?
We have shown in this work that IGF-1 could stimulate
glucose uptake and its incorporation into glycogen in IR-de-
¢cient ¢broblasts, which clearly indicates that IGF-1R pos-
sesses a metabolic potential. These e¡ects could also be ob-
tained upon stimulation of these cells by insulin. It is therefore
conceivable that in IR-de¢cient mice which become hyperin-
sulinemic, insulin, at high concentrations, might exert some of
its e¡ects through IGF-1R. This might partly explain the little
longer survival of these mutants as compared with mutant
mice lacking insulin [9^11]. Attempts to prolong the survival
of IR-de¢cient pups by injecting IGF-1 were unsuccessful [24].
It was, however, reported that IGF-1 injections could lower
hyperglycemia but did not reduce serum triglyceride levels.
This suggest that IGF-1R might be unable to stimulate lipo-
genesis in adipose cells and to prevent liver steatosis. The
derivation of cell lines from adipose tissue, muscle and liver
will make it possible to further assess whether and to what
extent IGF-1R can represent an alternative receptor for insu-
lin in these cells.
3.5. Mitogenic actions of IGFs and insulin through IGF-1R
or IR
The data presented in this work clearly show that both
IGF-1 and insulin were able to stimulate thymidine incorpo-
ration in IR-de¢cient ¢broblasts. In this context, it is interest-
ing to recall the results of some recent studies concerning the
ability of insulin or IGF-1/IGF-2 to lead to mitogenic e¡ects
exclusively through IR in cell lines lacking IGF-1R. One such
cell is a ¢broblast cell line derived from IGF-1R-de¢cient mice
[14]. It was reported that these cells, if overexpressing IR,
were able to proliferate in serum-free medium supplemented
only with insulin or IGF-2 whereas IGF-1 failed to promote
the growth of these cells [13]. Surprisingly, IGF-2 was even
more potent than insulin in promoting growth of these cells.
Another cell line lacking IGF-1R is the LB cell line derived
from a murine T-cell lymphoma that was insulin-dependent
for growth [25]. Insulin stimulated the incorporation of
[3H]thymidine in these cells [25,26]. Interestingly, the dose-
response curve for this mitogenic e¡ect of insulin through
IR was bell-shaped [27], like we observed in this work for
the mitogenic e¡ect of IGF-1 acting through IGF-1R. In
the LB cell line, negligible mitogenic e¡ects were observed
with IGF-1 and none with IGF-2 [25]. In IR-de¢cient ¢bro-
blasts, insulin was clearly able to lead to mitogenic e¡ects but
the dose-response curve was sigmoidal. The biological rele-
vance of the bell-shaped dose-response curves for the mito-
genic e¡ects of insulin acting through IR or IGF-1 acting
through IGF-1R still escapes our understanding and the
underlying molecular basis remains to be further explored.
It can, however, be recalled that a bell-shaped curve was pre-
viously reported for the action of growth hormone on lipo-
genesis in adipocytes [28]. It was demonstrated that growth
hormone binding to its receptor in solution resulted in the
formation of a dimer [29,30]. Receptor dimerization was crit-
ical for this biological e¡ect and the bell-shaped curve in this
case was explained by possible self-antagonism at high ligand
concentrations [28]. Since there appear to be some striking
di¡erences in the mitogenic action of insulin, IGF-1 and
IGF-2 through their homologous or heterologous receptors,
this must revive interest in further exploration for possible
di¡erences in the nature of the various ligand/receptor inter-
actions. Cell lines lacking IR or IGF-1R represent unique
tools for such studies.
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